You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 10,058,536

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,058,536

Title:	Pharmaceutical composition containing mirabegron
Abstract:	To provide: (1) a modified release liquid (suspension) containing mirabegron, (2) a ready-to-suspend pharmaceutical composition containing mirabegron, and (3) a mirabegron-containing pharmaceutical composition that does not generate undissolved lumps, even when it is suspended at the time of use. The present invention relates to a pharmaceutical composition containing a complex of mirabegron or a pharmaceutically acceptable salt thereof with sodium polystyrene sulfonate.
Inventor(s):	Takae; Seiji (Tokyo, JP), Sakai; Toshiro (Tokyo, JP), Kasashima; Yuki (Tokyo, JP), Ansei; Yurina (Tokyo, JP), Kiyota; Tsuyoshi (Tokyo, JP)
Assignee:	ASTELLAS PHARMA INC. (Tokyo, JP)
Application Number:	15/553,107
Patent Claims:	1. A pharmaceutical composition comprising a complex of mirabegron or a pharmaceutically acceptable salt thereof with sodium polystyrene sulfonate, a thickener, and a hydrophobic substance, wherein the hydrophobic substance is magnesium stearate and/or calcium stearate. 2. The pharmaceutical composition according to claim 1, wherein the content of the hydrophobic substance is 0.5% by weight to 35% by weight with respect to the weight of the thickener. 3. The pharmaceutical composition according to claim 1 or 2, wherein the thickener is one member or two or more members selected from the group consisting of xanthan gum, guar gum, locust bean gum, gellan gum, carboxymethyl cellulose sodium, gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, carrageenan, methylcellulose, sodium alginate, hypromellose, and polyvinyl alcohol. 4. The pharmaceutical composition according to claims 1 or 2 wherein the thickener is xanthan gum. 5. The pharmaceutical composition according to claim 1 or 2, wherein the content of the thickener is 1% by weight to 70% by weight with respect to the weight of the pharmaceutical composition. 6. The pharmaceutical composition according to claim 1 or 2, wherein the pharmaceutical composition is a ready-to-suspend pharmaceutical composition. 7. The pharmaceutical composition according to claim 1 or 2, wherein the pharmaceutical composition is a pharmaceutical composition for oral administration. 8. The pharmaceutical composition according to claim 1 or 2, wherein the pharmaceutical composition is a pharmaceutical composition for treating one member or two or more members selected from the group consisting of urinary urgency, urinary frequency, urge urinary incontinence, and neuropathic detrusor overactivity, which are associated with overactive bladder. 9. A method for modifying the release of mirabegron, the method comprising: administering a composition comprising a complex with mirabegron or a pharmaceutically acceptable salt thereof and sodium polystyrene, a thickener and a hydrophobic substance, wherein the hydrophobic substance is magnesium stearate and/or calcium stearate.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.